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by R. E. Staples*
Compounds intended for marketing by the
pharmaceutical industry are tested for possible
effects on reproductive processes in much the
same way today as was carried out even before
November 1961, when the drug thalidomide was
related to human malformations. At that time, ef-
fects on male and female fertility were sought,
but generally only for agents considered likely to
alter the endocrinologic status of the patient or
that were designed primarily for use by young
women. The test species was usually the rat.
When it became evident that this system did
not detect the teratogenic potential of
thalidomide, it was realized that a model that
would detect this type of activity was needed.
Thalidomide was under study in my laboratory at
the William S. Merrell Company (1) within three
days of Lenz's announcement of the relationship
between thalidomide and human malformations.
Hence, routine testing was being conducted in at
least one industrial laboratory when the FDA
guidelines were circulated in 1966. These
guidelines and the principles published by WHO
in 1967 have been followed by private industry,
which has conducted most of the routine testing
carried out to date to determine the teratogenic
potential of agents. These test results on prospec-
tive therapeutic agents now represent most of
the information available on the teratogenic
potential of chemicals. With the increased com-
mitment of resources currently available for the
testing of additional components of our en-
vironment, it is necessary to determine whether
such test procedures are doing the job.
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We have come to realize that the teratogenicity
of thalidomide represented the exception rather
than the rule for most tranquillizers and for drugs
in general. Today chemicals are known to be re-
sponsible for no more than 5% of the structural
malformations seen in man. Less than 25
chemicals are known teratogens in man, yet more
than 800 are identified as being teratogenic in
laboratory animals. Is this because man is more
resistant, or is this difference merely a reflection
ofthe difficulties encountered in determination of
positive teratogenicity in man? Of the human
malformations seen, 60% are still of unknown
etiology, in spite of continued testing. Does this
mean the value of the test system is in question,
that we have not tested the human teratogens
yet, or that most of the unidentified etiology in-
volve combinations of genetic and environmental
factors that are not present in test animals? Does
the high incidence of apparent false positives in
animal testing render the results of this testing
worthless? Are there alternative approaches
available now? Are potentially promising
techniques under investigation?
The presentations by the speakers of this
session were most interesting and provocative.
Palmer discussed the procedures routinely con-
ducted in test animals for determining
teratogenic potential and pointed out the value of
these tests. He emphasized the need for more
dedication to proper execution of the tests to
enhance predictive capability and to minimize
limitations. As viable alternatives to the in vivo
approach still are not available, he stressed the
need to apply information gained through testing
for toxicity, reproduction, and mutagenicity after
the evaluation of teratogenic investigations in or-
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An example of the progress being made in new
method development was presented by New, who
described the technique premitting extension of
the period of successful culture in vitro of the
post implantation rat embryo. This technique is
amenable to short-term investigations ofthe type
described, but as a test for teratogenic potential
more extensive application is dependent upon the
creation of an artificial placenta such that con-
tinued development of fetuses will be possible af-
ter experimentation. Several other methods are
being investigated that permit direct application
of test agent to the developing conceptus both in
vitro and in vivo, but unfortunately time did not
permit presentations or discussion of these
techniques.
Detection of functional deficits in animal off-
spring after intrauterine exposure to environ-
mental agents is an aspect of teratology that
has received only peripheral attention to date.
Hence, the current thinking of enzymologists
regarding the potential for detecting alterations
in enzyme function of offspring and the signifi-
cance of the alterations detected is of particular
importance. Andrew's presentation provided us
with the approaches being contemplated and the
realization that enzyme markers are still a long
way from providing a major contribution to our
test methodology.
The monitoring of human births for changes in
background incidence of malformations and
deficits is of major importance. In this regard,
not only do we have the experience of the
thalidomide episode, and several additional in-
cidents that involved fewer individuals, but the
realization that our exposure to potentially hazar-
dous agents has never been greater than it is
today. Flynt has provided us with a lucid over-
view of the role played by epidemiologists, the
approaches available to them, and the limitation
of each, and has given us an appreciation of the
extent of monitoring and surveillance that is
being carried out in the U.S. The system
described are likely to detect the most severe or
prevalent human teratogens missed through ap-
plication of animal models but it is unfortunate
that this information comes to light only after
children are affected. It is hoped that animal
model development someday will prevent such
human suffering.
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